Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner
Company Touts Nemvaleukin At Investor Day
Alkermes looks to keep parts of its nemvaleukin program in-house while also seeking a partner for its broader development. • Source: Shutterstock 
